NRC Health Q2 revenue rises on the back of product innovation
NRC•Outlook and analyst snapshot
NRC Health said it expects a strong second half of 2026 based on recent bookings performance. The company said it sees rising demand for healthcare experience improvement and governance solutions.
The one available analyst rating on the shares is buy. The median 12-month price target is $23.00, about 8.1% above the July 27 closing price of $21.27.
Q2 revenue and earnings beat estimates
NRC Health said second-quarter revenue rose 4% year over year to $35.4 million. Adjusted earnings per share for the quarter were $0.31, while GAAP net loss reflected stock and bonus costs.
The company also said total recurring contract value grew 11% year over year to $151.9 million.
Management cites product innovation and execution
The company said the quarter benefited from the commercialization of product innovations, along with strong go-to-market and solutions delivery execution.
Management described the rise in total recurring contract value as a leading indicator for future revenue.
